226 related articles for article (PubMed ID: 25093175)
21. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
Stewart JP; Thompson A; Santra M; Barlogie B; Lappin TR; Shaughnessy J
Br J Haematol; 2004 Jul; 126(1):72-6. PubMed ID: 15198734
[TBL] [Abstract][Full Text] [Related]
22. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
23. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.
Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
Br J Haematol; 2002 Jun; 117(3):626-8. PubMed ID: 12028033
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
26. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
[TBL] [Abstract][Full Text] [Related]
27. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
28. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
29. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
[TBL] [Abstract][Full Text] [Related]
30. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
[TBL] [Abstract][Full Text] [Related]
31. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
32. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.
Perfetti V; Coluccia AM; Intini D; Malgeri U; Vignarelli MC; Casarini S; Merlini G; Neri A
Am J Pathol; 2001 May; 158(5):1599-603. PubMed ID: 11337357
[TBL] [Abstract][Full Text] [Related]
33. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
35. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
36. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
[TBL] [Abstract][Full Text] [Related]
37. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
[TBL] [Abstract][Full Text] [Related]
38. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
39. Advances in biology of multiple myeloma: clinical applications.
Hideshima T; Bergsagel PL; Kuehl WM; Anderson KC
Blood; 2004 Aug; 104(3):607-18. PubMed ID: 15090448
[TBL] [Abstract][Full Text] [Related]
40. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
